Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

This study has been completed.
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00170170
First received: September 13, 2005
Last updated: February 1, 2010
Last verified: February 2010

September 13, 2005
February 1, 2010
November 2004
June 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00170170 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis

This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.

This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Recipients of liver, kidney, pancreas, heart or lung transplantation

  • Transplantation
  • Infection
  • Cytomegalovirus Infections
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
500
June 2007
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recipients of liver, kidney, pancreas, heart or lung transplantation
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00170170
2275-04, VAL101
Not Provided
Not Provided
Mayo Clinic
Roche Pharma AG
Principal Investigator: Raymund R. Razonable, M.D. Mayo Clinic
Mayo Clinic
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP